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Breast Cancer Therapy Annual is a concise and excellent
summary of the developments in the systemic therapy of
breast cancer over the past 5 years. As such it would be
as good a book as any other I have read for doctors train-
ing in the management of breast cancer, or other clinicians
who desire to bring their knowledge up to date. Similarly,
it would be suitable for non-clinical researchers who want
to update their knowledge of contemporary drug treatment
of breast cancer at the start of the 21st century.
The authors are a well-chosen group of international
opinion leaders whose knowledge of the clinical manage-
ment of breast cancer is exemplary. However, they have
not delved into the depths of that knowledge for this slim
and readable volume. The title suggests that one could
quickly get up to date with current thinking on the man-
agement of breast cancer, whereas I felt that the majority
of the contributors took the opportunity to cover where we
have been for the last five years, and less on the most
recent developments. Some of this is undoubtedly the
inevitable gap between writing and appearing in print, but
there remains an inconsistent inclusion of data available at
the end of 2001. The title is also somewhat misleading –
this was an opportunity to recognise that drug therapy is
not the only effective approach in the era of true multi-dis-
ciplinary management: but surgical and radiotherapeutic
developments get virtually no mention! On the other hand
there is an excellent chapter devoted to women with
BRCA1 & BRCA2, for which there is no systemic therapy
with proven survival benefits! There is also the inevitable
tension that spans the Atlantic Ocean, with less coverage
of European approaches by the North American contribu-
tors, and a bias towards what is standard of care in parts
of the USA. For example, the introduction assumes that
tamoxifen is given to all women with a diagnosis of DCIS,
which is certainly not the case in Europe!
There are some serious omissions, such as the absence of
any discussion on the possible advantage for taxanes in
tumours with p53 mutations (nor the randomised EORTC
trial testing this hypothesis). Surprising omissions in the
chapter on endocrine therapy are the lack of any of the
comparative data between the aromatase inhibitors and
tamoxifen in advanced disease, any mention of the pure
anti-oestrogen faslodex, or any discussion on the use of
these agents pre-operatively, and this was undoubtedly
the weakest chapter in the whole book.
For me the best chapters were those which covered the
EGF receptor family data, and the Ras pathway and
inhibitors, where a clear summary of the science was fol-
lowed by a robust coverage of the clinical data on such
biologically directed therapies.
Despite some reservations, this book does form an excel-
lent and readable summary covering the last 5 years. Over
the past 12 months there have been some considerable
developments in systemic therapy of breast cancer, and it
is somewhat disappointing that these are not included in a
book with a publication date of 2003.
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